XenoTech

Looking for new and scientific content and news from XenoTech? Then head over to BioIVT for valuable updates on research as well as normal and disease-state and related test systems for a variety of additional applications: https://www.linkedin.com/company/bioivt/

We’re looking forward to presenting a on “Antibody drug conjugates (ADCs): In Vitro Evaluation of Potential” at next week’s Gordon Research Conference on progressing (https://www.grc.org/drug-metabolism-conference/2023/). Request a meeting with Dr. Limaye if you’ll be attending or would like to discuss: https://hubs.ly/Q01WwM5R0 and make sure to follow BioIVT to access the poster once it’s available: https://www.linkedin.com/company/bioivt/

Abstract: Antibody drug conjugates (ADCs) are a novel modality leveraging monoclonal antibody (mAb)-mediated delivery of a cytotoxic payload molecule to its target. The small molecule conjugated to mAb can be released in unconjugated form and contribute to the drug-drug interaction (DDI) potential, therefore, both the antibody and the small molecule drug component should be considered. Here we present the summary and outcome of in vitro DDI studies conducted for several ADC programs at our facility. These studies included metabolic stability, metabolite identification, reaction phenotyping of CYPs and UGTs, CYP inhibition and induction potential, UGT inhibition potential, and potential as a substrate or inhibitor of transporters…

Did you miss our June Symposium? You can now access the recordings and slides for several of the presentations, including “Improving Predictions from Models: Model Selection, Protein Effects, and Regulation,” Potential of Major Pharmaceutical Excipients on Transporters and Enzymes” and “In Vitro Aspects of ICH M12, Industry and Technology” here:

Advanced In Vitro ADME Strategies: ICH Guidelines & Novel Methodologies - BioIVT Presentation Download a copy of BioIVT's presentations from the 2023 Advanced In Vitro ADME Strategies: ICH Guidelines & Novel Methodologies Symposium.

Since many compounds bind to red blood cells, which are 99% of cellular space in blood, determining parameters by only measuring drug concentration in plasma can significantly impact clearance and cause inaccuracies in calculations. That’s why the majority of polled researchers said they regularly conduct red blood cell partitioning with plasma protein binding studies. Read more: https://bioivt.com/blogs/why-do-most-polled-researchers-run-red-blood-cell-partitioning-studies-with-plasma-protein-binding?utm_source=XTsocial&utm_medium=XTsocial&utm_campaign=XTFacebook&utm_id=XTFacebook&utm_term=RBCpoll